ClinicaliQ Trial Snapshot
- Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies — Recruiting • Phase I • Oncology • NCT04068597.
- Drug being tested: CCS1477 (inobrodib), a novel therapeutic agent being evaluated for safety, tolerability, pharmacokinetics and biological activity in a Phase 1/2a trial across four haematological malignancies (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia, and High Risk Myelodysplastic Syndrome).
- Patient eligibility: The study enrolls patients with confirmed diagnoses of Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia, or High Risk Myelodysplastic Syndrome; specific eligibility criteria including disease status, prior treatment history and performance status would be detailed in the full protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Eligibility Snapshot
- : * Provision of consent * ECOG performance status 0-2 * Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML) * Must have previously received standard therapy * Adequate organ function
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.